Fig. 7

Tucidinostat increases the expression of the costimulatory molecules on human monocytes. a PBMCs from NSCLC patients (n=5) were cultured with increasing concentrations (2.5, 5, 7.5 μM) of tucidinostat for 24 h, respectively. Whereafter, the phenotype of peripheral blood monocytes (CD14⁺CD11b⁺) was assessed by FACS. Representative cytograms (left) or summary histograms (right) for the expression levels of HLA-DR and CD86 on gated monocytes within the PBMCs. b PBMCs from NSCLC patients were cultured with increasing concentrations (2.5, 5, 7.5 μM) of tucidinostat for 24 h, respectively. Whereafter, the phenotypes of CD4⁺ T cells (CD3⁺CD4⁺) and CD8⁺ T cells (CD3⁺CD8⁺) were assessed by FACS. Representative cytograms (left) or summary histograms (right) for the expression levels of CD69 on gated CD4⁺ and CD8⁺ T cells within the PBMCs. The error bars indicate mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA. ns not significant, CON control group, Tuc tucidinostat, PBMC peripheral blood mononuclear cell, NSCLC non-small cell lung cancer